Undertake the spillover effect and continue to invest in China, Boehringer Ingelheim participated in the 4th CIIE to practice the concept of "same health"

Shanghai, November 2, 2021/PRNewswire/ - At the 4th CIIE, Boehringer Ingelheim, a world-renowned R&D-driven biopharmaceutical company, will bring 500+100 square meters of double booths to fully demonstrate that companies are promoting mankind And innovations in animal health
.

The main booth of Boehringer Ingelheim, located in the medical equipment and medicine and health exhibition area in Hall 7.

Felix Gutsche, President and CEO of Boehringer Ingelheim China, said: “Participating in the CIIE for the third consecutive year represents our high value and long-term commitment to the Chinese market
.

At the same time, we are also benefiting from the spillover effect of the CIIE.

Grasp the opportunity of CIIE, exhibits will become commodities, exhibitors will become investors

This year is the third time that Boehringer Ingelheim has participated in the CIIE.
Thanks to the four major opportunities of international procurement, investment promotion, cultural exchanges, and open cooperation built by the CIIE, many of Boehringer Ingelheim’s star exhibits have accelerated into commodities.
The company's investment scale and speed have repeatedly hit new highs
.

At this CIIE, the main booth of Boehringer Ingelheim will launch an upgraded version of the "Stroke Total Solution" theme area
.

Boehringer Ingelheim’s patient-centered "Stroke Total Solution" concept blueprint debuted at the CIIE in 2019 and has now developed into a complete solution covering prevention, disease education, testing, first aid, diagnosis, treatment, Seven modules of rehabilitation

The CIIE is the first show of much-anticipated innovation
.

Boehringer Ingelheim’s first and debut products and solutions this year include: Spesolimab, the first of its kind in research, an IL-36R (interleukin-36 receptor) monoclonal antibody, which has been approved as a national drug The Center for Drug Evaluation (CDE) of the Supervision Administration has identified a breakthrough treatment drug for the treatment of generalized pustular psoriasis (GPP) and has recently submitted an application for registration; another star product, Europe Tang Jing® (enpagliflozin) new indication for the treatment of heart failure with reduced ejection fraction in adults is expected to be approved soon in China, and the indication for the treatment of heart failure with preserved ejection fraction in adults has also been submitted for registration in the near future Apply

In addition, the company will also showcase innovations in the field of animal health: the new swine vaccine mixing device TwistPak "space bottle" will make its world premiere at this CIIE, and will be the first to be listed in China worldwide; the world's first The animal health stem cell product ARTI-CELL® FORTE (a ready-to-use solution for the treatment of horse claudication) will also make its Asian debut at the CIIE
.

Global synchronization of new drugs, empowering Chinese innovation, and continuing to invest in China

In 2019, Boehringer Ingelheim’s “China Key” project was launched and made its debut at the CIIE
.

"Key to China" will fully incorporate China into the global early clinical development projects, which means that at the point of time when innovative drug registration is approved, China will be synchronized with Europe and the United States, or even earlier than Europe and the United States

During the current CIIE, a new batch of strategic partners will be signed for "Key China" projects, including a number of leading domestic top three or specialty hospitals, which will help "Key China" projects speed up again
.

In this year’s new biomedical area, Boehringer Ingelheim’s biopharmaceutical contract development and production service "Icebreaker Star" will also make a new appearance, and will establish cooperation with local innovative pharmaceutical companies to jointly promote the high-quality development of China’s biomedical industry.
Realize "China's innovation and go global"
.

In 2019, the Boehringer Ingelheim Biopharmaceutical Commercialized Contract Development and Production (CDMO) service platform debuted at the CIIE; this year, the production base completed the second phase of expansion, and its production capacity tripled
.

Up to now, Boehringer Ingelheim has invested nearly 200 million U.

Gao Qifei said: "As a family pharmaceutical company with a history of more than 100 years, the original intention and persistence of the family company allows us to look at the long-term, to determine long-term goals, achieve long-term investments, and complete long-term strategies
.

Now, our strategy in China is bearing fruit.

About Boehringer Ingelheim

Boehringer Ingelheim is committed to researching breakthrough therapies aimed at improving the health of humans and animals
.

As a R&D-driven global leading biopharmaceutical company, the company demonstrates value through innovation in areas where medical needs are highly unmet

About Boehringer Ingelheim China

Boehringer Ingelheim China is headquartered in Shanghai and currently has more than 4,000 employees nationwide.
Its core businesses include: human medicine, animal health and biopharmaceuticals
.
In recent years, Boehringer Ingelheim has achieved sustained growth in China, and its growth rate has exceeded the average growth level of the market.
It has been awarded the "China Outstanding Employer" certification for eight consecutive years
.
China is one of Boehringer Ingelheim’s most important strategic markets.
The company incorporates the needs of Chinese patients into its global R&D strategy, and is committed to bringing more and better innovative products to Chinese patients earlier, thereby improving people’s health and life Quality
.
The company has always been based on "rooting in China, serving China", and constantly deepen the development and growth of the Chinese market
.

Source: Boehringer Ingelheim